Black Bird Biotech Inc - BBBT STOCK NEWS

Black Bird Biotech (OTC PINK: BBBT) has confirmed through independent lab testing that its MiteXstream biopesticide is non-toxic to honey bees when ingested, with a 0% mortality rate after 48 hours. This follows previous results showing it is also non-toxic when applied topically. CEO Fabian Deneault emphasized these findings enhance the product's appeal in the agricultural sector. The biopesticides market is projected to reach $10.63 billion by 2027, growing at a CAGR of 13.1%, bolstered by rising research in microbial products.

Black Bird Biotech, Inc. (OTC PINK: BBBT) announced that its biopesticide MiteXstream has been confirmed as non-toxic to honey bees in an independent lab study conducted by STILLMEADOW, Inc.. The study revealed a 0% mortality rate in honey bees after 48 hours of exposure to MiteXstream. This positive outcome aligns with previous performance results and highlights MiteXstream's potential impact on sustainable agriculture. The biopesticide market is projected to reach $10.63 billion by 2027, growing at a CAGR of 13.1%.

Black Bird Biotech (OTC: BBBT) recently announced an interview with President Fabian Deneault, discussing the company's growth and MiteXstream biopesticide. Key highlights include ongoing sales and marketing initiatives, recent capital-raising efforts, and future opportunities for BBBT. The interview is available on multiple social media platforms and aims to inform stakeholders about the company's strategic direction.

MiteXstream is an EPA-registered biopesticide designed to combat pests and is marketed as a safe alternative to traditional pesticides.

Black Bird Biotech, Inc. (OTC:BBBT) announced the registration of its biopesticide MiteXstream in 43 states and D.C., with applications pending in six states, including California. The company appointed William J. LoBell as Executive V.P. of Sales and Development to spearhead marketing efforts for MiteXstream, which recently launched an Amazon store. LoBell, with extensive experience in product sales, is expected to enhance the company's market presence. MiteXstream offers 100% plant-based solutions, promising efficacy in pest control without hazardous residues.

Black Bird Biotech (OTC:BBBT) has signed a consulting agreement with Spire+, a sales and marketing firm, to enhance the growth of its biopesticide, MiteXstream. Spire+ will implement a comprehensive market strategy encompassing e-commerce and retail distribution. MiteXstream has recently secured an Efficacy Report validation and is already in use by cannabis growers in Montana. The partnership aims to broaden market reach and establish new sales channels, benefiting both commercial farmers and home gardeners.

Black Bird Biotech, Inc. (OTC PINK:BBBT) announced the release of the MiteXstream^TM Efficacy Report by Botanical Research in Motion, validating the biopesticide's effectiveness. This report supports the company's marketing strategy for MiteXstream^TM, which targets a growing global biopesticide market, valued at $78.7 billion in 2021 with a CAGR of 5.5% from 2016 to 2021. Preparations are underway to build a skilled team to pursue large industrial contracts and joint ventures globally.

Black Bird Biotech (OTC:BBBT) announced positive findings from an efficacy report on its biopesticide MiteXstreamTM conducted by Botanical Research in Motion. The report verifies MiteXstream's effectiveness against spider mites and powdery mildew, suggesting it as a safe alternative to chemical pesticides. The product can be utilized across various plants, indicating broader market potential. BBBT’s president stated MiteXstream could prevent billions in crop losses annually. The full report will be available on their website soon.

Black Bird Biotech expresses gratitude to all veterans and their families on Veterans Day. The company acknowledges the service of veterans and honors those who sacrificed their lives for freedom. Special thanks are given to current service members and directors of the company who have served in the military. Shareholders and potential investors are encouraged to stay updated through their Twitter account and website.

Black Bird Biotech, Inc. (OTC PINK: BBBT) has provided an update following the completion of its Regulation A funding round. The company repaid approximately $700,000 in convertible debt, leaving nearly $1 million for MiteXstream^TM sales investment. President Fabian Deneault emphasized the strong financial position to enhance shareholder value through sales and marketing efforts. BBBT is pursuing an uplisting to the OTCQB Venture Market, hopeful for approval soon. MiteXstream^TM, an EPA-registered biopesticide, is aimed at eradicating agricultural pests safely.